Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom
| Autor: | KA Büsing, J. von Hardenberg, Philipp Nuhn, Manuel Ritter |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Urology Salvage therapy urologic and male genital diseases 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Internal medicine Medicine Radiology Nuclear Medicine and imaging Clinical significance Psma pet ct Oligometastatic disease Neuroradiology Curative intent medicine.diagnostic_test business.industry Interventional radiology Primary cancer medicine.disease Clinical trial Prostate-specific antigen 030220 oncology & carcinogenesis Recurrent prostate cancer business |
| Zdroj: | Der Urologe. 56:1410-1416 |
| ISSN: | 1433-0563 0340-2592 |
| Popis: | Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy. In metastatic castration-resistant prostate cancer evidence for its use is not available. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink